Online First

NOVEMBER 4, 2019

FDA Accepts NDA Resubmission for Bupivacaine-Meloxicam Combination for Postoperative Pain

The FDA accepted a New Drug Application (NDA) resubmission for HTX-011 (bupivacaine-meloxicam, Heron Therapeutics), an investigational agent for the management of postoperative pain.

Related Content

Post-op Duration of Opioid Use, and Not

To read the full story, Log in or Sign up for a Free Account

First Name

Last Name

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select